Outcomes of hepatocellular carcinoma patients treated with sorafenib: a meta-analysis of Phase III trials.
Giuseppe CabibboAlessandro CucchettiCalogero CammàAndrea Casadei-GardiniCiro CelsaGiacomo Emanuele Maria RizzoPhilip JohnsonGiorgio ErcolaniPublished in: Future oncology (London, England) (2019)
Aim: To benchmark overall survival (OS) and time to radiological progression (TTP) of patients enrolled in randomized controlled trials (RCTs) assessing sorafenib in advanced hepatocellular carcinoma using individual participant survival data, and to meta-analyze prognostic factors for OS and TTP. Methods: RCTs were identified through literature search until December 2018. Individual participant survival was reconstructed with an algorithm from published Kaplan-Meier curves. Results: Ten RCTs were included. Median OS was 10.0 months (95% CI: 9.6-10.5), and median TTP was 4.1 months (95% CI: 3.8-4.3). Multivariable analyses showed HCV positivity, absence of macrovascular invasion and extra-hepatic disease as predictors of longer OS. Conclusion: We provided a benchmark for future studies on sorafenib. The present results can be used in the decision making for the early shift to second-line strategy.
Keyphrases
- prognostic factors
- phase iii
- end stage renal disease
- decision making
- randomized controlled trial
- free survival
- clinical trial
- open label
- ejection fraction
- newly diagnosed
- systematic review
- chronic kidney disease
- hepatitis c virus
- peritoneal dialysis
- machine learning
- electronic health record
- type diabetes
- phase ii
- cell migration
- weight loss
- hiv infected